Weekly reads: Vertex, stem cells for MS, Athersys, 900-day paper review at Nature
Vertex Pharmaceuticals has a lot going for it right now on the cell therapy front. For instance, they have the strongest type 1 diabetes cell therapy pipeline after some recent acquisitions. Still it’s not a simple matter to succeed in the cell therapy space even with one therapy for one targeted disease. Trials are tough […]
Weekly reads: Vertex, stem cells for MS, Athersys, 900-day paper review at Nature Read More »